CCT301-038 / Sunterra Biotech, Exuma Biotech - LARVOL DELTA

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov) - P1/2 | N=66 | Terminated | Sponsor: Shanghai PerHum Therapeutics Co., Ltd. | Active, not recruiting ➔ Terminated; Adjustment of study strategy

Metastases • Trial termination • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • AXL • ROR2

CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov) - P1 | N=9 | Terminated | Sponsor: Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Aug 2025 ➔ Oct 2024 | Recruiting ➔ Terminated; Adjustment of study strategy

Trial completion date • Trial termination • Oncology • Sarcoma • Solid Tumor • AXL

CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Dec 2023 ➔ Aug 2025 | Trial primary completion date: Feb 2023 ➔ Aug 2024

Trial completion date • Trial primary completion date • Oncology • Sarcoma • Solid Tumor • AXL

CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Jul 2023 ➔ Dec 2023 | Trial primary completion date: Aug 2022 ➔ Feb 2023

Trial completion date • Trial primary completion date • Oncology • Sarcoma • Solid Tumor • AXL

A Phase I Trial of CCT301-38 in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov) - P1; N=9; Recruiting; Sponsor: Shanghai PerHum Therapeutics Co., Ltd.

Clinical • New P1 trial • Oncology • Sarcoma • Solid Tumor • AXL • MRI

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov) - P1/2; N=66; Active, not recruiting; Sponsor: Shanghai PerHum Therapeutics Co., Ltd.; Trial completion date: Mar 2035 ➔ Jun 2023; Trial primary completion date: Jan 2021 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • AXL

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov) - P1/2; N=66; Active, not recruiting; Sponsor: Shanghai Sinobioway Sunterra Biotech; Recruiting ➔ Active, not recruiting

Enrollment closed